Recently, we have constructed a dual-hybrid direct random phase approximation method, called dRPA75, and demonstrated its good performance on reaction energies, barrier heights, and noncovalent interactions of main-group elements. However, this method has also shown significant but quite systematic errors in the computed atomization energies. In this paper, we suggest a constrained spin-component scaling formalism for the dRPA75 method (SCS-dRPA75) in order to overcome the large error in the computed atomization energies, preserving the good performance of this method on spin-unpolarized systems at the same time. The SCS-dRPA75 method with the aug-cc-pVTZ basis set results in an average error lower than 1.5 kcal mol for the entire n-homodesmotic hierarchy of hydrocarbon reactions (RC0-RC5 test sets). The overall performance of this method is better than the related direct random phase approximation-based double-hybrid PWRB95 method on open-shell systems of main-group elements (from the GMTKN30 database) and comparable to the best O(N)-scaling opposite-spin second-order perturbation theory-based double-hybrid methods like PWPB95-D3 and to the O(N)-scaling RPAX2@PBEx method, which also includes exchange interactions. Furthermore, it gives well-balanced performance on many types of barrier heights similarly to the best O(N)-scaling second-order perturbation theory-based or spin-component scaled second-order perturbation theory-based double-hybrid methods such as XYG3 or DSD-PBEhB95. Finally, we show that the SCS-dRPA75 method has reduced self-interaction and delocalization errors compared to the parent dRPA75 method and a slightly smaller static correlation error than the related PWRB95 method.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1021/acs.jctc.6b01140 | DOI Listing |
Prim Care Companion CNS Disord
January 2025
Eisai Inc, Nutley, New Jersey.
Insomnia and some insomnia treatments can impact an individual's daytime functioning. Here, we performed post hoc analyses of patient-reported outcomes from a phase 3 clinical trial to assess the impact of lemborexant (LEM), a dual orexin receptor antagonist, on daytime functioning. Adults with insomnia were randomized 1:1:1 to receive placebo, LEM 5 mg (LEM5) or LEM 10 mg (LEM10) for 6 months.
View Article and Find Full Text PDFEur J Heart Fail
January 2025
Department of Medicine, University of Chicago Medicine, Chicago, IL, USA.
Aims: This post hoc analysis aimed to assess the efficacy and safety of the non-steroidal mineralocorticoid receptor antagonist finerenone by baseline diuretic use in FIDELITY, a pre-specified pooled analysis of the phase III trials FIDELIO-DKD and FIGARO-DKD.
Methods And Results: Eligible patients with type 2 diabetes (T2D) and chronic kidney disease (CKD; urine albumin-to-creatinine ratio [UACR] ≥30-<300 mg/g and estimated glomerular filtration rate [eGFR] ≥25-≤90 ml/min/1.73 m, or UACR ≥300-≤5000 mg/g and eGFR ≥25 ml/min/1.
Cureus
December 2024
Research and Development, Glenmark Pharmaceuticals Limited, Mumbai, IND.
Background Cough in common cold is often associated with rhinorrhoea and nasal congestion, requiring treatment with a cough suppressant, decongestant, and antihistamine. Bilastine is a non-sedating antihistamine, a preferred option over sedating antihistamines. A combination of bilastine, dextromethorphan, and phenylephrine is expected to provide non-sedating treatment for cough associated with a common cold or allergy.
View Article and Find Full Text PDFJ Clin Hypertens (Greenwich)
January 2025
Department of Cardiology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China.
This study aimed to assess the efficacy and safety of a combination therapy of Allisartan Isoproxil 240 mg and Amlodipine 5 mg (ALI/AML) compared to AML 5 mg monotherapy in patients with mild-to-moderate essential hypertension. In this phase III, multicenter, double-blind, parallel-group, randomized controlled trial, patients aged 18-70 years with mean sitting systolic blood pressure (msSBP) between 140 and <180 mmHg and mean sitting diastolic blood pressure (msDBP) between 90 and <110 mmHg, following a 4-week treatment with AML 5 mg, were randomized 1:1 to receive either ALI/AML or AML once daily for 12 weeks. This 12-week double-blind period was followed by an open-label extension of ALI/AML treatment through week 52.
View Article and Find Full Text PDFDiabetes Obes Metab
January 2025
Boehringer Ingelheim International GmbH, Biberach, Germany.
Aim: To explore the effects of sex and baseline body mass index (BMI) on the efficacy and safety of survodutide in people with a BMI ≥27 kg/m.
Materials And Methods: Totally 387 people (aged 18-75 years, BMI ≥27 kg/m, without diabetes) were randomized 1:1:1:1:1 to once-weekly subcutaneous survodutide (0.6, 2.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!